Rengalin tablets d / rassas., No. 20

Rengalin is indicated for use in adults and children from 3 years of age.

productive and unproductive cough with influenza and ARVI, acute pharyngitis, laryngotracheitis, acute obstructive laryngitis, chronic bronchitis and other infectious-inflammatory and allergic diseases of the upper and lower respiratory tract.

The drug is taken orally. At one time - 1 tablet (keep in the mouth until completely dissolved). The risk is not intended for dividing the tablet into parts.

Apply 1-2 tabs. 3 times / day outside meals. Depending on the severity of the condition in the first 3 days, the frequency of administration can be increased up to 4-6 times / day.

The duration of therapy depends on the severity of the disease and is determined by the attending physician.

Lozenges from white to almost white, flat-cylindrical, beveled, scored on one flat side, with solid edges; the flat side with scribble has the inscription MATERIA MEDICA, the other flat side has the inscription RENGALIN.

1 tab.

antibodies to bradykinin affinity purified 0.006 g *

antibodies to histamine affinity purified 0.006 g *

antibodies to morphine affinity purified 0.006 g *

* applied to isomalt in the form of a mixture of three active aqueous-alcoholic dilutions of the substance, diluted 10012, 10030, 10050 times, respectively.

Excipients: isomalt - 0.506 g, microcrystalline cellulose - 0.0275 g, magnesium stearate - 0.0055 g, anhydrous citric acid - 0.005225 g, colloidal silicon dioxide - 0.00275 g, sodium cyclamate - 0.00275 g, sodium saccharin - 0.000275 g.

• Children under 3 years of age (due to insufficient data on efficacy and safety);

• increased individual sensitivity to the components of the drug.

pharmachologic effect

It has been shown experimentally that the components of the preparation modify the activity of the ligand-receptor interaction of endogenous regulators with the corresponding receptors: antibodies to morphine with opiate receptors; antibodies to histamine - with histamine H1 receptors; antibodies to bradykinin - with B1-bradykinin receptors; while the combined use of the components leads to an increase in the antitussive effect.

In addition to the antitussive action, the complex drug, due to its components, has anti-inflammatory, anti-edema, antiallergic, antispasmodic (antibodies to histamine, antibodies to bradykinin) and analgesic action (antibodies to morphine).

The complex drug Rengalin, due to the modification of histamine-dependent activation of H1 receptors and bradykinin-dependent activation of B2 receptors, selectively reduces the excitability of the cough center of the medulla oblongata, inhibits the central links of the cough reflex. Oppressing the centers of pain sensitivity in the thalamus, it blocks the transmission of pain impulses to the cerebral cortex. Inhibits the flow of pain impulses from the periphery due to a decrease in the release of tissue and plasma algogens (histamine, bradykinin, prostaglandins and others). Unlike narcotic analgesics, it does not cause respiratory depression, drug dependence, does not have narcogenic and hypnotic effects.

Eases the manifestations of acute pharyngitis, laryngitis and bronchitis, reducing bronchospasm. It relieves systemic and local symptoms of allergic reactions by influencing the synthesis and release of histamine and bradykinin from mast cells.

Pharmacokinetics

The sensitivity of modern physicochemical methods of analysis (gas-liquid chromatography, high-performance liquid chromatography, gas chromatography-mass spectrometry) does not allow assessing the content of the active substances of Rengalin in biological fluids, organs and tissues, which makes it technically impossible to study pharmacokinetics.

Side effect

Possible reactions of increased individual sensitivity to the components of the drug.

Application during pregnancy and lactation

The safety of using Rengalin in pregnant women and during breastfeeding has not been studied. If necessary, taking the drug should take into account the benefit / risk ratio.

Application in children

The use of the drug in children under 3 years of age is contraindicated (due to insufficient data on efficacy and safety).

special instructions

Before using Rengalin, you should consult your doctor.

Influence on the ability to drive vehicles and mechanisms

Rengalin does not affect the ability to drive vehicles and other potentially dangerous mechanisms.

Overdose

In case of an accidental overdose, dyspeptic phenomena are possible due to the fillers included in the preparation.

Drug interactions

To date, no cases of incompatibility with other drugs have been registered.